Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Shares, with no par value
-
Shares outstanding
-
51M
-
Number of holders
-
27
-
Total 13F shares, excl. options
-
12.8M
-
Shares change
-
+10.8M
-
Total reported value, excl. options
-
$75.3M
-
Value change
-
+$64M
-
Number of buys
-
22
-
Number of sells
-
-4
-
Price
-
$5.90
Significant Holders of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) as of Q3 2025
29 filings reported holding EPRX - EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value as of Q3 2025.
EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) has 27 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12.8M shares
of 51M outstanding shares and own 25.14% of the company stock.
Largest 10 shareholders include Beutel, Goodman & Co Ltd. (4.06M shares), Balyasny Asset Management L.P. (1.35M shares), Vivo Capital, LLC (1.35M shares), SCOTIA CAPITAL INC. (1.28M shares), GREAT POINT PARTNERS LLC (1.2M shares), Ally Bridge Group (NY) LLC (915K shares), Logos Global Management LP (900K shares), ROYAL BANK OF CANADA (429K shares), Velan Capital Investment Management LP (352K shares), and Affinity Asset Advisors, LLC (300K shares).
This table shows the top 27 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.